STEWARDSHIPS OF HEPATITIS C VIRUS PATIENTS IN PRISONS

M.D. GIL-SIERRA¹, F. TELLEZ-PEREZ², E. RIOS-SANCHEZ¹, M.D.P. BRICEÑO-CASADO¹, S. FENIX-CABALLERO¹, C. MARTINEZ-DIAZ¹, E.J. ALEGRE-DEL REY¹, C. PALOMO-PALOMO¹, J. DIAZ-NAVARRO¹, J.F. LOPEZ-VALLEJO¹, J.M. BORRERO-RUBIO¹.

¹HOSPITAL UNIVERSITARIO DE PUERTO REAL, PHARMACY, PUERTO REAL, SPAIN.

²HOSPITAL UNIVERSITARIO DE PUERTO REAL, INTERNAL MEDICINE SERVICE, PUERTO REAL, SPAIN

4CPS-085


J05 - Antivirals for systemic use

BACKGROUND

- ✓ To **eliminate** hepatitis C virus (HCV) infection in institutionalized patients is necessary to reduce risk of transmission in general population.
- ✓ There is a **high prevalence** of HCV infection in **prision population** (PP).

PURPOSE

To develop a multidisciplinary program for diagnosis and treatment of HCV infection in PP of 3 prisions and evaluate the effectiveness and safety of treatment for HCV.



SECURITY

CONCLUSION

103/114(90.4%) SVR12

136/143(95.1%) EOT

HCV recurrence: 4 (2.2%) patients

EFFECTIVENESS

1. The multidisciplinary program allowed diagnosed and treated all PP with HCV infection, although some withdrawal treatments were recorded. 2. EOT and SVR12 were achieved in the most patients. An AE leading a death.



1 (0.5%) hepatic decompensation

(0.5%) death

http://www.eahp.eu/2 4-4CPS-085